Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 1
2009 1
2013 1
2014 2
2019 1
2020 5
2021 7
2022 6
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean higashi osaka (5,406 results)?
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Shitara K, et al. N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469182 Clinical Trial.
Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
Kawazoe A, Ando T, Hosaka H, Fujita J, Koeda K, Nishikawa K, Amagai K, Fujitani K, Ogata K, Watanabe K, Yamamoto Y, Shitara K. Kawazoe A, et al. Among authors: hosaka h. Lancet Gastroenterol Hepatol. 2021 Mar;6(3):209-217. doi: 10.1016/S2468-1253(20)30396-4. Epub 2021 Jan 26. Lancet Gastroenterol Hepatol. 2021. PMID: 33508242 Clinical Trial.
Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer.
Yamaguchi K, Minashi K, Sakai D, Nishina T, Omuro Y, Tsuda M, Iwagami S, Kawakami H, Esaki T, Sugimoto N, Oshima T, Kato K, Amagai K, Hosaka H, Komine K, Yasui H, Negoro Y, Ishido K, Tsushima T, Han S, Shiratori S, Takami T, Shitara K. Yamaguchi K, et al. Among authors: hosaka h. Cancer Sci. 2022 Aug;113(8):2814-2827. doi: 10.1111/cas.15462. Epub 2022 Jul 1. Cancer Sci. 2022. PMID: 35701865 Free PMC article. Clinical Trial.
Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study.
Kawabata R, Chin K, Takahari D, Hosaka H, Muto O, Shindo Y, Nagata N, Yabusaki H, Imamura H, Endo S, Kashiwada T, Nakamura M, Hihara J, Kobayashi M, Sagawa T, Saito S, Sato A, Yamada T, Okano N, Shimada K, Matsushima M, Kataoka M, Matsumoto S, Goto M, Kotaka M, Shiraishi T, Yamai H, Nagashima F, Ishizuka N, Yamaguchi K. Kawabata R, et al. Among authors: hosaka h. Gastric Cancer. 2023 Nov;26(6):1020-1029. doi: 10.1007/s10120-023-01423-z. Epub 2023 Aug 23. Gastric Cancer. 2023. PMID: 37610558 Free PMC article. Clinical Trial.
Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study.
Nakazawa N, Sohda M, Ubukata Y, Kuriyama K, Kimura A, Kogure N, Hosaka H, Naganuma A, Sekiguchi M, Saito K, Ogata K, Sano A, Sakai M, Ogawa H, Shirabe K, Saeki H. Nakazawa N, et al. Among authors: hosaka h. Ann Surg Oncol. 2022 Nov;29(12):7400-7406. doi: 10.1245/s10434-022-12226-4. Epub 2022 Jul 20. Ann Surg Oncol. 2022. PMID: 35857197 Review.
Ramucirumab-related Oral Pyogenic Granuloma: A Report of Two Cases.
Aragaki T, Tomomatsu N, Michi Y, Hosaka H, Fukai Y, Iijima M, Yoda T. Aragaki T, et al. Among authors: hosaka h. Intern Med. 2021 Aug 15;60(16):2601-2605. doi: 10.2169/internalmedicine.6650-20. Epub 2021 Mar 8. Intern Med. 2021. PMID: 33678742 Free PMC article.
Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial.
Chin K, Takahari D, Kawabata R, Hosaka H, Saitou SO, Shiraishi T, Yabusaki H, Goto M, Nakamura M, Imamura H, Shindo Y, Nagashima F, Ichikawa W, Saotome T, Yamamoto W, Ishizuka N, Yamaguchi K. Chin K, et al. Among authors: hosaka h. Anticancer Res. 2022 May;42(5):2683-2687. doi: 10.21873/anticanres.15746. Anticancer Res. 2022. PMID: 35489762 Clinical Trial.
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).
Shitara K, Doi T, Hosaka H, Thuss-Patience P, Santoro A, Longo F, Ozyilkan O, Cicin I, Park D, Zaanan A, Pericay C, Özgüroğlu M, Alsina M, Makris L, Benhadji KA, Ilson DH. Shitara K, et al. Among authors: hosaka h. Gastric Cancer. 2022 May;25(3):586-597. doi: 10.1007/s10120-021-01271-9. Epub 2022 Jan 8. Gastric Cancer. 2022. PMID: 34997449 Free PMC article. Clinical Trial.
Albumin-derived Neutrophil-to-Lymphocyte Ratio Score as a Marker of Nivolumab Treatment Sensitivity in Gastric Cancer: A Multicenter Study.
Nakazawa N, Sohda M, Tateno K, Watanabe T, Kimura A, Kogure N, Hosaka H, Naganuma A, Sekiguchi M, Saito K, Ogata K, Sano A, Sakai M, Ogawa H, Shirabe K, Saeki H. Nakazawa N, et al. Among authors: hosaka h. In Vivo. 2023 Mar-Apr;37(2):818-824. doi: 10.21873/invivo.13147. In Vivo. 2023. PMID: 36881071 Free PMC article.
25 results